Coya Therapeutics has raised about $11.1 million in a private investment round to support commercial-readiness efforts for COYA 302,…
Articles by Michela Luciano, PhD
Patient enrollment has reached the halfway mark in an ongoing expanded access program (EAP) for MN‑166 (ibudilast), Medicinova’s oral…
Note: This story has been updated Jan. 16, 2026, to correct that once the therapy is delivered, the gene, not…
Aperture Therapeutics said it is advancing its RNA-targeting therapy APRTX-003 as a potential treatment for amyotrophic lateral sclerosis…
Some people with amyotrophic lateral sclerosis (ALS) who received Qalsody (tofersen) in the VALOR trial experienced improvements in…
NUZ-001, an investigational oral therapy being developed by Neurizon Therapeutics for the treatment of amyotrophic lateral sclerosis (ALS), is…
The U.S. Food and Drug Administration (FDA) has cleared the start of a pivotal Phase 3 clinical trial testing the…
The ALS Association is awarding $20,000 grants to 107 eligible clinics across the U.S. to help strengthen multidisciplinary care…
Former Texas A&M University football player Chris Larkin is returning to the university’s campus in College Station, widely known as…
The first participant has been enrolled in a large Italian clinical trial that’s testing Avextra’s cannabis-based medicine for managing…